Top

Published in:

01-08-2012 | Review

Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care

Authors: Nimesh SA Patel, Kiran K Nandra, Christoph Thiemermann

Published in: Critical Care | Issue 4/2012

Abstract

Erythropoietin (EPO) is known to have numerous biological functions. Its primary function in the body is to increase red blood cell numbers by way of preventing the apoptosis of erythroid progenitor cells via the homodimeric EPO receptor. The discovery that the local production of EPO within the brain in response to hypoxia or ischemia protects neurons against injury via an anti-apoptotic effect formed the basis of the hypothesis that the local generation of EPO limits the extent of injury. Although the hypothesis proved to be true in pre-clinical models of ischemia/reperfusion injury and inflammation, the randomized, controlled clinical trials that followed demonstrated serious adverse events of EPO due to activation of the hematopoietic system. Consequently, derivatives of EPO that lacked erythropoietic activity were discovered to reduce injury in many pre-clinical models associated with ischemia and inflammation. Unfortunately, there are no published clinical trials to determine the efficacy of non-erythropoietic derivatives of EPO in humans.

Sasaki R: Pleiotropic functions of erythropoietin. Intern Med. 2003, 42: 142-149. 10.2169/internalmedicine.42.142.PubMedCrossRef

Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998, 95: 4635-4640. 10.1073/pnas.95.8.4635.PubMedPubMedCentralCrossRef

Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004, 22: 63-69. 10.1097/01.shk.00001276869.21260.9d.PubMedCrossRef

Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C: Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2003, 48: 3544-3556. 10.1002/art.11351.PubMedCrossRef

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003, 102: 1340-1346. 10.1182/blood-2003-01-0223.PubMedCrossRef

Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C: Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004, 66: 983-989. 10.1111/j.1523-1755.2004.00847.x.PubMedCrossRef

Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003, 198: 971-975. 10.1084/jem.20021067.PubMedPubMedCentralCrossRef

Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004, 19: 348-355.PubMedCrossRef

Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002, 8: 495-505.PubMedPubMedCentral

10.

Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C, EPO Stroke Trial Group: Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009, 40: e647-656. 10.1161/STROKEAHA.109.564872.PubMedCrossRef

11.

Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007, 357: 965-976. 10.1056/NEJMoa071533.PubMedCrossRef

12.

Patel NS, Collino M, Yaqoob MM, Thiemermann C: Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care. 2011, 1: 40-10.1186/2110-5820-1-40.PubMedPubMedCentralCrossRef

13.

Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004, 305: 239-242. 10.1126/science.1098313.PubMedCrossRef

14.

Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 2010, 77: 1020-1030. 10.1038/ki.2010.25.PubMedCrossRef

15.

Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL: Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008, 65: 285-297. 10.1097/TA.0b013e31817f2c6e. discussion 297-289PubMedCrossRef

16.

Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M: Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab. 2001, 21: 857-864.PubMedCrossRef

17.

Goldwasser E, Kung CK, Eliason J: On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 1974, 249: 4202-4206.PubMed

18.

Fukuda MN, Sasaki H, Lopez L, Fukuda M: Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989, 73: 84-89.PubMed

19.

Dong YJ, Kung C, Goldwasser E: Receptor binding of asialoerythropoietin. J Cell Biochem. 1992, 48: 269-276. 10.1002/jcb.240480307.PubMedCrossRef

20.

Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LØ, Cerami-Hand C, Wuerth JP, Cerami A, Brines M: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA. 2003, 100: 6741-6746. 10.1073/pnas.1031753100.PubMedPubMedCentralCrossRef

21.

Okada T, Sawada T, Kubota K: Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation. 2007, 84: 504-510. 10.1097/01.tp.0000277672.02783.33.PubMedCrossRef

22.

Mori S, Sawada T, Okada T, Kubota K: Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery. 2008, 143: 556-565. 10.1016/j.surg.2007.12.013.PubMedCrossRef

23.

Sato T, Tanno M, Miki T, Yano T, Shimamoto K, Miura T: Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO. Cardiovasc Drugs Ther. 2010, 24: 401-408. 10.1007/s10557-010-6265-5.PubMedCrossRef

24.

Mun KC, Golper TA: Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purification. 2000, 18: 13-17. 10.1159/000014403.PubMedCrossRef

25.

Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993, 268: 11208-11216.PubMed

26.

Grodberg J, Davis KL, Sykowski AJ: Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur J Biochem. 1993, 218: 597-601. 10.1111/j.1432-1033.1993.tb18413.x.PubMedCrossRef

27.

Satake R, Kozutsumi H, Takeuchi M, Asano K: Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta. 1990, 1038: 125-129. 10.1016/0167-4838(90)90020-G.PubMedCrossRef

28.

Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R: A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2005, 102: 2046-2051. 10.1073/pnas.0409329102.PubMedPubMedCentralCrossRef

29.

Imamura R, Isaka Y, Ichimaru N, Takahara S, Okuyama A: Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun. 2007, 353: 786-792. 10.1016/j.bbrc.2006.12.099.PubMedCrossRef

30.

Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004, 101: 14907-14912. 10.1073/pnas.0406491101.PubMedPubMedCentralCrossRef

31.

Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG: Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell. 2001, 104: 291-300. 10.1016/S0092-8674(01)00213-6.PubMedCrossRef

32.

Stomski FC, Woodcock JM, Zacharakis B, Bagley CJ, Sun Q, Lopez AF: Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors. J Biol Chem. 1998, 273: 1192-1199. 10.1074/jbc.273.2.1192.PubMedCrossRef

33.

Hanazono Y, Sasaki K, Nitta H, Yazaki Y, Hirai H: Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochem Biophys Res Commun. 1995, 208: 1060-1066. 10.1006/bbrc.1995.1442.PubMedCrossRef

34.

Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA: The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997, 90: 1867-1873.PubMed

35.

Campana WM, Misasi R, O'Brien JS: Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med. 1998, 1: 235-241.PubMed

36.

Ebie AZ, Fleming KG: Dimerization of the erythropoietin receptor transmembrane domain in micelles. J Mol Biol. 2007, 366: 517-524. 10.1016/j.jmb.2006.11.035.PubMedCrossRef

37.

Brines M, Cerami A: Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008, 264: 405-432. 10.1111/j.1365-2796.2008.02024.x.PubMedCrossRef

38.

Brines M, Cerami A: The receptor that tames the innate immune response. Mol Med. 2012, 18: 486-496.PubMedPubMedCentralCrossRef

39.

Um M, Gross AW, Lodish HF: A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal. 2007, 19: 634-645. 10.1016/j.cellsig.2006.08.014.PubMedCrossRef

40.

Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM: Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998, 395: 511-516. 10.1038/26773.PubMedCrossRef

41.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 2008, 105: 10925-10930. 10.1073/pnas.0805594105.PubMedPubMedCentralCrossRef

42.

Patel NS, Nandra KK, Brines M, Collino M, Wong WS, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiemermann C: A non-erythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med. 2011, 17: 883-892.PubMedPubMedCentralCrossRef

43.

Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI: A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med. 2011, 17: 194-200.PubMedPubMedCentralCrossRef

44.

Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M: Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci USA. 2010, 107: 14357-14362. 10.1073/pnas.1003019107.PubMedPubMedCentralCrossRef

45.

Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A: ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology. 2011, 115: 1084-1092. 10.1097/ALN.0b013e31822fcefd.PubMedCrossRef

46.

Wu H, Liu X, Jaenisch R, Lodish HF: Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995, 83: 59-67. 10.1016/0092-8674(95)90234-1.PubMedCrossRef

47.

Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA, REVEAL Investigators: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011, 305: 1863-1872. 10.1001/jama.2011.592.PubMedPubMedCentralCrossRef

48.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009, 361: 2019-2032. 10.1056/NEJMoa0907845.PubMedCrossRef

49.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006, 355: 2085-2098. 10.1056/NEJMoa065485.PubMedCrossRef

50.

Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009, 30: 253-260. 10.1159/000223229.PubMedCrossRef

51.

Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y: Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery. 2009, 146: 506-514. 10.1016/j.surg.2009.03.022.PubMedCrossRef

52.

Xu K, George I, Klotz S, Hay I, Xydas S, Zhang G, Cerami A, Wang J: Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure. J Cardiovasc Pharmacol. 2010, 56: 506-512. 10.1097/FJC.0b013e3181f4f05a.PubMedCrossRef

53.

Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A: Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant. 2008, 17: 135-141. 10.3727/000000008783907044.PubMedCrossRef

54.

Cassis P, Azzollini N, Solini S, Mister M, Aiello S, Cugini D, Scudeletti P, Gagliardini E, Abbate M, Gallon L, Remuzzi G, Noris M: Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. Transplantation. 2011, 92: 271-279. 10.1097/TP.0b013e3182241106.PubMedCrossRef

55.

Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M, Leist M, Blomgren K: The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem. 2004, 91: 900-910. 10.1111/j.1471-4159.2004.02769.x.PubMedCrossRef

56.

Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N, Yilmaz O, La Torre D, Buemi M, Iacopino DG, Coleman T, Cerami A, Brines M, Tomasello F: Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine. 2006, 4: 310-318. 10.3171/spi.2006.4.4.310.PubMedCrossRef

57.

Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Beek J, Leist M, Brines M, Cerami A, Ghezzi P: Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med. 2006, 12: 153-160.PubMedPubMedCentralCrossRef

58.

Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Nitta N, Haneda M, Koya D, Uzu T, Kashiwagi A: Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol. 2008, 19: 321-328. 10.1681/ASN.2007040481.PubMedPubMedCentralCrossRef

59.

Price CD, Yang Z, Karlnoski R, Kumar D, Chaparro R, Camporesi EM: Effect of continuous infusion of asialoerythropoietin on short-term changes in infarct volume, penumbra apoptosis and behaviour following middle cerebral artery occlusion in rats. Clin Exp Pharmacol Physiol. 2010, 37: 185-192. 10.1111/j.1440-1681.2009.05257.x.PubMedCrossRef

60.

Nakazawa J, Isshiki K, Sugimoto T, Araki S, Kume S, Yokomaku Y, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T: Renoprotective effects of asialoerythropoietin in diabetic mice against ischaemia-reperfusion-induced acute kidney injury. Nephrology (Carlton). 2010, 15: 93-101. 10.1111/j.1440-1797.2009.01170.x.CrossRef

61.

Yamashita T, Nonoguchi N, Ikemoto T, Miyatake S, Kuroiwa T: Asialoerythropoietin attenuates neuronal cell death in the hippocampal CA1 region after transient forebrain ischemia in a gerbil model. Neurol Res. 2010, 32: 957-962. 10.1179/016164110X12700393823336.PubMedCrossRef

62.

Ogino A, Takemura G, Kawasaki M, Tsujimoto A, Kanamori H, Li L, Goto K, Maruyama R, Kawamura I, Takeyama T, Kawaguchi T, Watanabe T, Moriguchi Y, Saito H, Fujiwara T, Fujiwara H, Minatoguchi S: Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol. 2010, 56: 1949-1958. 10.1016/j.jacc.2010.04.068.PubMedCrossRef

63.

Sasaki N, Sekiguchi M, Kikuchi S, Konno S: Effects of asialo-erythropoietin on pain-related behavior and expression of phosphorylated-p38 map kinase and tumor necrosis factor-alpha induced by application of autologous nucleus pulposus on nerve root in rat. Spine (Phila Pa 1976). 2011, 36: E86-94. 10.1097/BRS.0b013e3181f137a8.CrossRef

Title: Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care
Authors: Nimesh SA Patel
Kiran K Nandra
Christoph Thiemermann
Publication date: 01-08-2012
Publisher: BioMed Central
Published in: Critical Care / Issue 4/2012
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc11315

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

A Review of Transfusion Therapy: Clinical Principles and Practice, 3rd edition

Clinical review: Volume of fluid resuscitation and the incidence of acute kidney injury - a systematic review

Vitamin D in sepsis: from basic science to clinical impact

Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis

The Barcelona Declaration from the World Alliance against Antibiotic Resistance: engagement of intensivists

Effects of endotoxin on lactate metabolism in humans